25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC ...
Read More >
Shamrock Foods Company, 369 N.L.R.B. No. 5 (January 7, 2020) is the latest in the National Labor Rel...
Read More >
The National Labor Relations Board ("NLRB") is expected to rewrite its rules protecting employees wh...
Read More >
Brief Takeaway: Plan sponsors that offer employer stock in their benefit plans can breathe a sigh o...
Read More >
Seyfarth Synopsis: As the Massachusetts Paid Family and Medical Leave (“PFML”) law enters the firs...
Read More >
The CFIUS real estate regulations reflect a new emphasis on real estate transactions based on proxim...
Read More >